Key result
Icariin alleviates hepatic steatosis in PCOS rats by boosting mitochondrial fatty acid oxidation.
Why the study?
It was unclear whether and how icariin can ameliorate hepatic steatosis in polycystic ovary syndrome.
Does icariin improve hepatic steatosis and lipid metabolism in a rat model of NAFLD with PCOS?
Population
Female Sprague Dawley rats with NAFLD induced by high-fat diet and letrozole
Comparison
Icariin treatment vs untreated model rats
Design
Preclinical study with RNA-sequence, qRT-PCR, and Western blot analyses
Follow-up
28 days
Authors
Loading...
May support icariin for steatosis in PCOS models; hypothesis-generating and leaves open human translation.
Does icariin improve hepatic steatosis and lipid metabolism in a rat model of NAFLD with PCOS?
p-value: p=<0.05
In a rat model of PCOS with NAFLD, icariin ameliorated hepatic steatosis by improving fatty acid oxidation and reducing lipid accumulation.
Hai et al. (2023) studied Nonalcoholic fatty liver disease in polycystic ovary syndrome (n=36). Icariin vs. Vehicle (1% CMC) was evaluated on Hepatic steatosis and lipid accumulation (Oil Red O stained area, serum TG, liver TG) (p=<0.05). Icariin significantly alleviated hepatic steatosis and lipid accumulation in a rat model of PCOS by increasing mitochondrial fatty acid oxidation and decreasing fatty acid synthesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: